Unity Biotechnology, Inc. – NASDAQ:UBX
Unity Biotechnology stock price today
$0.176
-0.82
-82.38%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Unity Biotechnology stock price monthly change
-35.55%
month
Unity Biotechnology stock price quarterly change
-35.55%
quarter
Unity Biotechnology stock price yearly change
-47.42%
year
Unity Biotechnology key metrics
Market Cap | 16.20M |
Enterprise value | 52.18M |
P/E | -0.31 |
EV/Sales | 221.12 |
EV/EBITDA | -1.78 |
Price/Sales | 74.42 |
Price/Book | 0.26 |
PEG ratio | N/A |
EPS | -2.52 |
Revenue | N/A |
EBITDA | -41.36M |
Income | -37.62M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -13606.75% |
Oper. margin | -12958.72% |
Gross margin | 100% |
EBIT margin | -12958.72% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeUnity Biotechnology stock price history
Unity Biotechnology stock forecast
Unity Biotechnology financial statements
| Jun 2023 | 0 | -12.20M | |
|---|---|---|---|
| Sep 2023 | 0 | -15.28M | |
| Dec 2023 | 1.90M | -4.33M | -228.13% |
| Mar 2024 | 0 | -5.79M |
| 2025 | 2.5M | -40.78M | -1631.23% |
|---|---|---|---|
| 2026 | 25.72M | -31.97M | -124.28% |
| 2027 | 56.12M | 886.41K | 1.58% |
| 2028 | 84.86M | 8.86M | 10.44% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 101008000 | 51.60M | 51.09% |
|---|---|---|---|
| Sep 2023 | 69270000 | 33.06M | 47.73% |
| Dec 2023 | 65690000 | 37.29M | 56.77% |
| Mar 2024 | 58863000 | 34.87M | 59.25% |
| Jun 2023 | -11.08M | 9.85M | -2.62M |
|---|---|---|---|
| Sep 2023 | -7.11M | 14.24M | -18.37M |
| Dec 2023 | -7.57M | 15.11M | 4.38M |
| Mar 2024 | -5.18M | -7.19M | 0 |
Unity Biotechnology alternative data
| Aug 2023 | 31 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 32 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 19 |
| Jun 2024 | 19 |
| Jul 2024 | 19 |
Unity Biotechnology other data
9.80%
-90.20%
of UBX is owned by hedge funds
26
-25
930.58K
-4.32M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 2389 |
| Jul 2023 | 0 | 1020 |
| Aug 2023 | 0 | 581 |
| Sep 2023 | 0 | 1246 |
| Oct 2023 | 0 | 1024 |
| Nov 2023 | 0 | 589 |
| Jan 2024 | 0 | 1183 |
| Feb 2024 | 0 | 680 |
| May 2024 | 0 | 603 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 603 | $1.55 | $935 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 603 | $1.55 | $935 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 680 | $1.71 | $1,163 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 680 | $1.71 | $1,163 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 1,183 | $1.71 | $2,023 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 1,183 | $1.71 | $2,023 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 589 | $1.83 | $1,078 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 589 | $1.83 | $1,078 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 1,024 | $1.9 | $1,946 | ||
Sale | GHOSH ANIRVAN director, officer.. | Common Stock, $0.0001 par value | 1,024 | $1.9 | $1,946 |
-
What's the price of Unity Biotechnology stock today?
One share of Unity Biotechnology stock can currently be purchased for approximately $0.18.
-
When is Unity Biotechnology's next earnings date?
Unfortunately, Unity Biotechnology's (UBX) next earnings date is currently unknown.
-
Does Unity Biotechnology pay dividends?
No, Unity Biotechnology does not pay dividends.
-
How much money does Unity Biotechnology make?
Unity Biotechnology has a market capitalization of 16.20M.
-
What is Unity Biotechnology's stock symbol?
Unity Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "UBX".
-
What is Unity Biotechnology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Unity Biotechnology?
Shares of Unity Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Unity Biotechnology's key executives?
Unity Biotechnology's management team includes the following people:
- Dr. Anirvan Ghosh Chief Executive Officer & Director(age: 61, pay: $758,570)
- Dr. Jamie Dananberg Chief Medical Officer(age: 67, pay: $625,590)
- Ms. Lynne Marie Sullivan Chief Financial Officer & Head of Corporation Devel.(age: 59, pay: $471,360)
-
How many employees does Unity Biotechnology have?
As Jul 2024, Unity Biotechnology employs 19 workers, which is 14% less then previous quarter.
-
When Unity Biotechnology went public?
Unity Biotechnology, Inc. is publicly traded company for more then 7 years since IPO on 3 May 2018.
-
What is Unity Biotechnology's official website?
The official website for Unity Biotechnology is unitybiotechnology.com.
-
Where are Unity Biotechnology's headquarters?
Unity Biotechnology is headquartered at 285 East Grand Avenue, South San Francisco, CA.
-
How can i contact Unity Biotechnology?
Unity Biotechnology's mailing address is 285 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 04161192.
Unity Biotechnology company profile:
Unity Biotechnology, Inc.
unitybiotechnology.comExchange:
NASDAQ
Full time employees:
19
Industry:
Biotechnology
Sector:
Healthcare
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
285 East Grand Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001463361
ISIN: US91381U2006
CUSIP: 91381U101
